Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia
- Author(s)
- McQuilten, ZK; Busija, L; Seymour, JF; Stanworth, S; Wood, EM; Kenealy, M; Weinkove, R; Australasian Leukaemia and Lymphoma Group (ALLG);
- Details
- Publication Year 2022-03,Volume 63,Issue #3,Page 676-683
- Journal Title
- Leukemia & Lymphoma
- Publication Type
- Research article
- Abstract
- Myelodysplastic syndromes (MDS) have a major impact on quality of life (QoL). We performed a post hoc analysis of two multicenter trials of azacitidine-based disease-modifying therapy for patients with MDS and low blast count acute myeloid leukemia (AML), to identify factors associated with QoL. 231 patients were included (median age 70 years). At baseline, higher initial hemoglobin, but not neutrophil or platelet count, was associated with better global QoL and physical function (p < 0.001 and p = 0.001, respectively). During therapy, increase in hemoglobin was associated with improvement in QoL and physical function (p = 0.005 and p < 0.001, respectively). Lower initial hemoglobin was associated with higher dyspnea and fatigue scores (p < 0.001 and p = 0.001, respectively), and hemoglobin response was associated with improvement in dyspnea and fatigue (p < 0.001 for each). In patients with MDS and low blast count AML, hemoglobin level was strongly correlated with global QoL, physical functioning, dyspnea and fatigue, both before and during azacitidine-based therapy.
- Keywords
- Aged; Antimetabolites, Antineoplastic/adverse effects; Azacitidine/adverse effects; Dyspnea/drug therapy/etiology; Fatigue/etiology; Hemoglobins; Humans; *Leukemia, Myeloid, Acute/diagnosis/drug therapy; *Myelodysplastic Syndromes/diagnosis/drug therapy; Quality of Life; Myelodysplastic syndrome; acute myeloid leukemia; azacitidine; hemoglobin; red cell transfusion
- Department(s)
- Haematology
- PubMed ID
- 34915809
- Publisher's Version
- https://doi.org/10.1080/10428194.2021.2012664
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-01-31 05:10:58
Last Modified: 2025-01-31 05:11:49